Sun Pharma Announces Launch Of Generic Exelon(R) In US

Main Category: Alzheimer's / Dementia
Also Included In: Parkinson's Disease;  Regulatory Affairs / Drug Approvals
Article Date: 07 Jul 2010 - 1:00 PDT

email to a friend   printer friendly   opinions  

Sun Pharma announced launch of generic Exelon®, rivastigmine tartrate capsules for the US market. Earlier, USFDA had granted final approval for the Company's ANDA to market these products.

These generic rivastigmine capsules are therapeutically equivalent of Novartis Exelon® Capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths of Exelon® have annual sales of approximately USD 130 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Exelon® with a para IV certification, shares a 180-day marketing exclusivity.

Rivastigmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson's disease.

Exelon ® is a registered trademark of Novartis.

Source:
Sun Pharma

• Additional
• References
• Citations